DNTP002234
dGTP
| dNTP Pool | |
|---|---|
| This entry does not belong to any pool in the database. |
| Members of control pools |
|---|
| N/A |
|
Last modified: 10/Sep/2021
| Results | |
|---|---|
| Publication |
Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, Kilpatrick JM, Morris P, Chand P, Babu YS: Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.,
Int Immunopharmacol, 2010
PubMed |
| Value | 6.23 | Dimension | pmol/106 cell |
| Error (standard error of the mean) | 0.93 |
| Data presentation in publication | diagram |
| Source | |
|---|---|
| Source organism |
human
(Homo sapiens)
Taxonomy 9606 |
| Sample source | primary cells |
| Cell line/type as in publication | lymphocytes |
| Compartment | whole cell |
| Experiment Details | |
|---|---|
| Measurement type | dNTP incorporation assay |
| Extraction method | methanol |
| Remarks to measurement type | Sherman and Fyfe |
| Growth conditions | IL-2 stimulated; growed 72h |
| Treatment | |
|---|---|
| Drug/stress type | drug |
| PubChem | 135565454 , 135398592 |
| Applied drug | BCX-4208, dGuo |
| Treatment details/effects | Purine nucleoside phosphorylase (LACC1) inhibition |
| Genes and Proteins | |
|---|---|
| No genes or proteins manipulated. | |